US 9,808,419 B2
Medicinal treatment of dermal infectious disorders with norketotifen
A. K. Gunnar Aberg, Sarasota, FL (US); and Vincent B. Ciofalo, Branford, CT (US)
Assigned to BRIDGE PHARMA, INC, Sarasota, FL (US)
Filed by BRIDGE PHARMA, INC., Sarasota, FL (US)
Filed on Mar. 16, 2016, as Appl. No. 15/71,546.
Application 15/071,546 is a continuation of application No. 14/437,534, abandoned, previously published as PCT/US2013/067177, filed on Oct. 29, 2013.
Application 14/437,534 is a continuation in part of application No. 13/744,807, filed on Jan. 18, 2013.
Claims priority of provisional application 61/720,058, filed on Oct. 30, 2012.
Prior Publication US 2016/0193143 A1, Jul. 7, 2016
Int. Cl. A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/10 (2006.01); A61K 31/4535 (2006.01); A61K 45/06 (2006.01); A61K 31/56 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/573 (2006.01); A61K 47/02 (2006.01); A61K 9/107 (2006.01); A61K 9/127 (2006.01); A61K 9/20 (2006.01)
CPC A61K 9/0014 (2013.01) [A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/10 (2013.01); A61K 9/107 (2013.01); A61K 9/127 (2013.01); A61K 9/2054 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/4535 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01)] 9 Claims
 
1. A method of treating skin infections in a human patient suffering from a skin infection, consisting of topically administering a topical formulation to skin of a human patient that is infected with a bacterium or a fungus, wherein the topical formulation consists of a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient,
wherein the topically applied RS-norketotifen or pharmaceutically acceptable salt thereof inhibits the growth of the bacterium or fungus, and
wherein the RS-norketotifen or pharmaceutically acceptable salt thereof is the only active antimicrobial agent in the topical formulation.